Lennox-Gastaut Syndrome: A State of the Art Review. by Mastrangelo, Mario
Lennox–Gastaut Syndrome: A State of the
Art Review
Mario Mastrangelo1
1Division of Pediatric Neurology, Department of Pediatrics, Child
Neurology and Psychiatry, Sapienza-University of Rome, Rome, Italy
Neuropediatrics
Address for correspondence Mario Mastrangelo, MD, PhD, Division of
Pediatric Neurology, Department of Pediatrics, Child Neurology and
Psychiatry, “La Sapienza-University of Rome,” Via dei Sabelli
108-00141, Rome, Italy (e-mail: mario.mastrangelo@uniroma1.it).
Introduction
Lennox–Gastaut syndrome (LGS) is an electroclinical syn-
drome, with onset in the prescholar or scholar ages, includ-
ing three distinct hallmarks: (1) multiple seizure types
(mainly tonic, atonic, and atypical absences); (2) interictal
diffuse 1.5 to 2.5 Hz slow spike-and-wave discharges during
the wake state, and paroxysmal fast activity during the sleep
state at the electroencephalogram (EEG); and (3) intellectual
disability and/or behavior disorders.1,2
Epidemiology
LGS accounts for 3 to 5% of childhood epilepsies and involves
7% of the childrenwith intellectual disability (55% of patients
with LGS have an intellectual quotient under 50).2,3 The
onset of seizures is usually between 1 and 8 years of age.1–3
Males to females ratio is approximately 5 to 1 (prevalence
10 per 100,000 versus 2 per 100,000).2,3 A prior West
syndrome can be assessed in 10 to 25% of patients with
LGS.2,3 Different studies evidenced a similar prevalence of
LGS in Europe and United States (0.1–0.28 per 1,000 live
births) with an incidence of approximately 2 per 100,000
children per year (0.6% of all new-onset epilepsies).2,3
Etiology
An identifiable cause of LGS can be defined in about 70%
of the cases, and it is usually represented by a static brain
disorder while progressive metabolic diseases are very
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Abstract Lennox–Gastaut syndrome (LGS) is a severe age-dependent epileptic encephalopathy
usually with onset between 1 and 8 years of age. Functional neuroimaging studies
recently introduced the concept of Lennox–Gastaut as “secondary network epilepsy”
resulting from dysfunctions of a complex system involving both cortical and subcortical
structures (default-mode network, corticoreticular connections, and thalamus). These
dysfunctions are produced by different disorders including hypoxic–ischemic enceph-
alopathies, meningoencephalitis, cortical malformations, neurocutaneous disorders,
or tumors. The list of etiologies was expanded to pathogenic copy number variants at
whole-genome array comparative genomic hybridization associated with late-onset
cases or pathogenic mutations involving genes, such as GABRB3, ALG13, SCN8A, STXBP1,
DNM1, FOXG1, or CHD2. Various clinical trials demonstrated the usefulness of different
drugs (including rufinamide, clobazam, lamotrigine, topiramate, or felbamate), keto-
genic diet, resective surgery, corpus callosotomy, and vagus nerve stimulation in the
treatment of epileptic manifestations. The outcome of LGS often remains disappoint-
ing regarding seizure control or cognitive functioning. The realization of animal
models, which are still lacking, and the full comprehension of molecular mechanisms
involved in epileptogenesis and cognitive impairment would give a relevant support to
further improvements in therapeutic strategies for LGS patients.
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rare.2,3 Several etiologies including hypoxic–ischemic en-
cephalopathies, meningoencephalitis, tuberous sclerosis
complex, cerebral malformations, monogenic disorders,
chromosomal abnormalities, tumors (such as hypothalamic
hamartomas) or idiopathic intracranial hypertension can be
involved.1–5
Despite their rare occurrence some inborn errors of
metabolism, such as biotinidase defects or disorders of
creatine metabolism, have a relevant importance because
of the availability of specific effective treatments.2
Recent data demonstrated that LGS children with history
of birth hypoxia or other perinatal events have more severe
epilepsy with an earlier onset and a higher incidence of
delayed milestones.6 No significant difference in number of
antiepileptic drugs consumed, motor deficits or magnetic
resonance imaging (MRI) abnormalities were detected in the
comparisonwith LGS patientswithout evidences of perinatal
events.6
Whole-genome array comparative genomic hybridization
identified pathogenic or potentially pathogenic copy number
variants in 8 out of 21 adult patients with LGS of unknown
etiology.7 Cases of late-onset LGS were described in adult
patients with 15q11.1q13.3 or 15q11.2-q13.1 duplication.8,9
Various gene mutations causing cortical malformations
(i.e., LIS1, DCX or GPR56) or neurocutaneous syndromes
(TSC1 and TSC2) have been frequently associated with
LGS.10 The causative role of mutations in other genes (such
as GABRB3, ALG13, SCN8A, STXBP1, DNM1, FOXG1 or CHD2)
have been elucidated in recent exome studies or in case
reports in patients with LGS without a history of infantile
spasms.11–13 A heteroplasmic variant in the mitochondrial
MT-ND1 gene, resulting in a reduced stability of the protein,
was recently demonstrated in a patient with a LGS evolving
from a West syndrome.14 A pathogenic mutation in SCN1A
gene was reported in 1 out of 22 Norwegian adult patients
with LGS.15 In this patient epileptic pattern mainly included
myoclonic seizures.15
Pathophysiological Hypothesis
The comprehension of the pathophysiology of LGS has
always been limited because of the lack of an animal model,
a very slow progression of the studies on the genetic basis of
the syndrome and the existence of multiple etiologies.16
LGS is an epileptic encephalopathy in which epileptic
seizures are directly responsible for a severe impairment
of cognitive, motor, and sensorial functions.16–18 It shares
with Ohtahara syndrome and West syndrome, that occur
earlier, the condition of “age-dependent epileptic encepha-
lopathy” in which common electroclinical pathways are
activated by an insult acting in a specific period of brain
development.17–19 The promoting insult can be realized by
different etiologies that can impair awide range ofmolecular
and neuronal mechanisms.17,18,20,21 Transition between
West syndrome and LGS after the first year of life denote
that the related epileptic manifestations and the involved
neuronal networks can be activated by similar epileptogenic
processes.18 These processes result in distinct phenotypes
according to the different period of brain maturation in
which the promoting insult occur.18 Specific molecular
mechanisms that regulate the transition between pheno-
types of West syndrome and LGS are still unknown.18
The impairment or the instability of complex networks
involving different cortical and subcortical structures seems
the first common step toward the LGS electroclinical pheno-
type.20,21 In this context, LGS can be conceptualized as a
“secondary network epilepsy,” in which epileptic activity
(including both seizures and epileptic discharges) is ampli-
fied through intrinsic cognitive cerebral networks.20,21 The
EEG hallmarks of LGS suggest a widespread cortical activa-
tion during ictal and interictal epileptic activity and different
functional neuroimaging studies confirmed the involvement
of diffuse zones of association cortex and spares primary
cortical regions in the epileptogenesis.20–22 Generalized
paroxysmal fast activity and 1.5 to 2.5 Hz diffuse slow spike
and waves were interpreted as the electroencephalographic
expression of the activation of distinct neuronal networks
in a simultaneous functional MRI (fMRI)-EEG study on
13 patients.22 Generalized paroxysmal fast activity was
associated with a diffuse recruitment of association cortices,
brainstem, thalamus, and basal ganglia while diffuse
1.5 to 2.5 Hz slow spike and waves-related fMRI pattern
included combined cortical/subcortical activations and
deactivations.22
Some authors proposed that an abnormal recruitment
of intrinsic attention and default-mode networks could
contribute to a rapid amplification of epileptic activity
within a cascade including corticoreticular and reticulospi-
nal connections.21,23 Focal lesions causing LGS, such as
cortical malformations, probably produce chronic interfer-
ences with these networks.23 The association of different
types of cortical lesions with LGS and the control of
epileptic manifestations after their surgical ablation support
the prominent importance of cortical networks and, subse-
quently, the secondary role of subcortical structures in
the epileptogenesis.21,22 Thalamus probably plays a role of
synchronizer and amplifier rather than a seizure focus.21
This hypothesis was consistent with the demonstration of
a thalamic activation in only 4 out of 13 patients with diffuse
slow spike andwaveswho recently underwent simultaneous
EEG-3 Tesla fMRI.21,22 An ictal–interictal single-photon
emission computed tomography study during video-EEG
recording in seven patients with LGS demonstrated that
pons is involved in the pathogenesis of tonic seizures within
a corticoreticular network including bilateral frontal and
parietal association areas.21,23
Transcranial magnetic stimulation data detected a lower
interictal cortical excitability in 18 adult LGS patients than in
control groups including 40 patients with other refractory
epilepsies and 20 healthy nonepileptic subjects.24 Lower
interictal cortical excitability could contribute to the cogni-
tive, sensorimotor, and behavioral regression that is usually
observed in LGS even if no similar studies are available
for other epileptic encephalopathies.24Different recent stud-
ies suggested other mechanisms involved in cognitive
impairment induced by epileptic manifestations.24,25
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Concurrent EEG-fMRI data on 15 LGS adult patients demon-
strated an abnormal interaction between cognitive networks
(default-mode, dorsal attention, executive control, and ante-
rior salience) both in ictal phases and in periods in which no
scalp-detectable epileptic activity was present.25 These re-
sults evidenced that the impaired functioning of neuronal
networks involved in cognitive processes may endure after
the acute phases of epileptic seizures.25 Task-free fMRI
evidenced an increased connectivity in critical areas of
association cortex and a decreased connectivity in primary
cortex of nine adult LGS patients with severe epileptic
phenotypes.26 In the same study abnormal network connec-
tivity was also demonstrated in other structures involved in
cognitivemechanisms, such as brainstem, limbic system, and
striatum.26
Clinical Presentation
The association of characteristic multiple seizure types, the
specific EEG pattern and intellectual disability represents the
classic hallmark of LGS and remains the basis for the diagno-
sis.2,17,19 This diagnostic triad is not necessarily completely
present at the onset of seizures and a precise diagnosis of LGS
often requires time to be formulated.1,2,17,19
Seizure Types
Tonic seizures (►Fig. 1, parental informed consent was
obtained), atypical absences, and atonic seizures (►Fig. 2)
are the most common seizure types in LGS. Drop attacks
(tonic or atonic falls) often results in frequent traumatic
injuries (►Fig. 2).1,2,17,19 Nonconvulsive status epilepticus
can be observed in 50 to 75% of LGS patients and it is often
represented by subcontinous atypical absenceswith variable
degrees of consciousness impairment with or without
recurring brief tonic seizures.1,2,17,19 Other seizure types,
including focal seizures with or without secondary generali-
zation or tonic–clonic generalized seizures, are more com-
mon in the later stages of LGS in early adolescence and
adulthood.1,17
Intellectual Disability
Most of patients with LGS presents with intellectual disabili-
ty and behavioral problems (aggression, hyperactivity, or
autistic spectrum) including different degrees of severi-
ty.1–3,17 Cognitive impairment worsen in cases with a high
recurrence of seizures and interictal epileptic activity,
according to the actually accepted concept of “epileptic
encephalopathy,” even if it can also be secondary to the
underlying causes of LGS and not only to epileptic activity
itself.27 A cognitive impairment involves up to 95% of
patients within 5 years from the onset of epilepsy.2,3,17 Up
to 10 to 20% of patients with LGS reaches acceptable ranges
of intellectual functioning despite variable limitations in
daily activities and cases of lacking cognitive impairment
have been recently reported.2,28 Main risk factors for intel-
lectual delay in LGS include earlier age of onset, a previous
West syndrome, a symptomatic etiology, and episodes of
nonconvulsive status epilepticus.1,2,17,29
Electroencephalogram Patterns
The two typical EEG features of LGS are represented by 1.5
to 2.5 Hz diffuse slow spike and waves and generalized
paroxysmal fast activity (►Fig. 3).2,17,30,31
Fig. 1 Seizure types in Lennox–Gastaut syndrome: a tonic seizure in an 11-year-old boy.
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In adulthood sleep, EEG remains the most important
diagnostic tool for LGS because the recording of a diffuse
paroxysmal fast activity during slow sleep is more constant
than diffuse slow spike-wave discharges during wakeful-
ness.30 In a recent retrospective study of 27 adults between
40 and 59 years of age, EEG showed persistence of general-
ized paroxysmal fast activity in all subjects while diffuse
slow spike-wave discharges persisted in only 7 of them.30
Diagnostic Investigations
The detailed clinical evaluation and the realization of both
awake and sleepEEG represents theminimumrequired for the
diagnosis.2,17 Physical examination should identify neurolog-
ical deficits, hypomelanotic macules, fibromas, or heart mur-
mur.2,17 Retinal abnormalities or visual impairment should be
excluded.1,2 In addition to the developmental history, neuro-
psychological assessments at the time of diagnosis and during
the follow-up reveal the degree of intellectual disability and
the eventual cognitive deterioration.1,2,17,19
Sleep EEG with video and overnight video-EEG with
electromyogram electrodes are recommended if available
in the resource setting.2,17
Neuroimaging is useful for the characterization ofmorpho-
logic brain abnormalities (cortical malformations, such as
lissencephaly or polymicrogyria, tuberous sclerosis complex,
neoplasia, hypoxic–ischemic encephalopathy) (►Fig. 4).1,2Re-
cent data outlined that all LGS patients, independently by the
etiology, have a minor whole brain volume than healthy
subjects with a prominent involvement of mesial frontal
region, bilateral anterior temporal poles, and reticular forma-
tion.32 Functional neuroimaging including fMRI, positron
emission tomography, and single-photon emission computed
tomographyoffers a contribution in thepresurgical evaluation
of well localized epileptogenic areas.33
Genetic workup should include array comparative geno-
mic hybridization or selected genes sequencing should be
guided by clinical suspect.2
Pharmacological Treatment
No international guidelines exist for the pharmacological
treatment of LGS because of the paucity of available clinical
Fig. 3 EEG of patients with Lennox–Gastaut syndrome: (A) Diffuse 1.5 to 2.5 Hz spike and slow waves; (B) paroxysmal fast activity. Filter PA 5.30
Hz, filter PB 70 Hz, amplitude EEG 100 μV/cm. EEG, electroencephalogram.
Fig. 2 Seizure types in Lennox–Gastaut syndrome: clinical presen-
tation of an atonic seizure (Image courtesy Dr. Luana Berillo, De-
partment of Pediatrics, Child Neurology and Psychiatry, Sapienza-
University of Rome, Rome, Italy).
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trials.34,35 The choice of antiepileptic drugs at the onset is
tailored to seizures types, clinical presentation, and EEG
patterns and its principles are the same that are currently
used for all epilepsies.34 In the common clinical practice,
valproate is used as a first-line treatment because of
its efficacy in both focal and generalized seizures while
lamotrigine and topiramate are possible alternatives in
the following steps.34 Other drugs, including rufinamide,
felbamate, clobazam and zonisamide are used in add-on as
second-line treatment.34
Rufinamide
Rufinamide resulted in amedian reduction in total seizures of
32.7% (vs. a decrease of 11.7% in placebo group) in a double-
blinded, randomized, placebo-control study in 138 patients
(age range: 4–30 years).36 A subsequent open label extension
study, enrolling 124 out of 138 original patients, demonstrat-
ed a reduction of more than 50% of both total seizures and
tonic–atonic seizures frequency in 45.1% of patients.37 Similar
data were obtained in a randomized, double-blind placebo-
controlled trial in 59 Japanese patients aged between 4 and
30 years.38 In this study, a higher decrease of tonic–atonic and
total seizures frequency was reported in patients receiving
rufinamide than in placebo group (24.2% and 32.9 vs.
3.3% and 3.1%, respectively).38 A following open-label
extension of this study on 41 out of the original 59 patients
demonstrated comparable benefits in the long-term period in
both tonic–atonic and total seizure control with the use of
rufinamide.39
An efficacy of rufinamide was also suggested for 40
children under age 4 with drug-resistant epilepsies, includ-
ing only 4 LGS patients.40 This aspect represents a relevant
methodological limit because data from other epileptic
syndromes cannot be applicated to LGS (LGS patients have
a higher retention rate for rufinamide).41 A recent interim
analysis of an in progress multicenter, randomized, active-
controlled, open-label study evidenced a similar profile of
safety and pharmacokinetic features of rufinamide in LGS
children between 1 and 4 years and in children older than
4 years.42 A responder rate of 33.3% for total seizures (57.1%
for drop attacks) was also demonstrated in a sample of
31 LGS adults aged between 18 and 37 years.43
Some clinically relevant drug interactions of rufinamide
should always be considered in LGS patients with poly-
therapy (rufinamide increases phenytoin serum concen-
trations, while valproate increases rufinamide serum
concentrations).35,44
Clobazam
Two randomized controlled studies (a phase II and a phase
III) and a related multicentre, open-label extension study, in
which clobazam was used as adjunctive therapy, recently
demonstrated more than 50% of seizure reduction in
more than 50% of the enrolled LGS patients.45–48 None of
the other drugs with the approval of U.S. Food and
Drugs Administration for LGS treatment produced similar
results.46–48 Reported reduction of drop attacks frequency in
the two randomized controlled studies was approximately
12% for patients treated with a low dosage of clobazam
(0.25 mg/kg/d) while it ranged between 68.3 and 85%
in patients treated with high dosages (1 mg/kg/d).46–48
Responder rate ranged between 77.6 and 83% in patients
who received 1 mg/kg/d of clobazam.46–48 The subsequent
open-label extension study reported a median decrease in
weekly drop seizures of 91.6 and 79.5% of the enrolled
subjects experienced a reduction in weekly drop seizures
more than 50% from baseline at 24 months.49 The introduc-
tion of clobazam resulted in an improvement of global
functioning in the concomitant use of other antiepileptic
drugs.46–49 No differences between different age groups
were defined regarding efficacy and safety.49
Lamotrigine
No recent data on the use of lamotrigine in LGS are avail-
able.34 A reduction of 32% of generalized seizures frequency
was observed in an old double-blind placebo-controlled trial
in 169 LGSpatients (79 treatedwith lamotrigine as an add-on
therapy and 90 with placebo).50 In this trial, no significant
differenceswere observed in themain side effects (especially
severe skin reactions) between patients treated with lamo-
trigine and patients who received placebo.50
Topiramate
A reduction ranging from 14.8 to 58% of drop attacks was
assessed in two main studies in which topiramate was
Fig. 4 Neuroimaging findings in patients with Lennox–Gastaut
syndrome: (A) Lissencephaly type 1 in a 6-year-old female patient;
(B) polymicrogyria (arrows) in a 5-year-old female patient;
(C) subependymal nodules (tuberous sclerosis complex) in a
7-year-old male patient; (D) hypothalamic hamartoma (arrows) in a
9-year-old female patient.
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administered in the add-on.51,52 In one of these studies a
median reduction of 25.8% in major motor seizures was
recorded in patients who received topiramate at a target
dose of 6 mg/kg/d (vs. an increase of 5.1% in the placebo
group).51
Felbamate
Felbamate is indicated as an add-on therapy in selected LGS
patients inwhomprevious antiepileptic drugs did not obtain
an adequate seizure control.34,35 The best results with
felbamate were obtained in the treatment of drop attacks
(reduction of seizures frequency ranging from 34 to 50%)
with a significant improvement of the quality of life.25,34 The
most severe side effect and limiting factor of felbamate is
aplastic anemia notwithstanding its rare occurrence (34
cases in the United States in the period 1994–2006).35,53
Patients with high risk for aplastic anemia (history of cyto-
penia, autoimmune disorder or positive antinuclear anti-
body titer) should not receive felbamate.35
Other Antiepileptic Drugs
The spectrum of antiepileptic drugs that have been used in
the clinical practice in LGS patients also includes clonaze-
pam, zonisamide, and lacosamide.35,40,54,55 The weak evi-
dences for efficacy in LGS for these drugs were collected in
uncontrolled studies on small samples.34,35 Recent risks of
exacerbation of tonic and astatic seizures were recently
reported in LGS adults treated with lacosamide.55
A recent open-label uncontrolled trial including 30
patients with LGS treated with cannabidiol evidenced a
median reduction of 36.8% of motor seizures over a period
of 12 weeks of treatment with a prominent efficacy in atonic
(68.8%) and tonic seizures (44%).56 An online parental
survey including 24 patients with LGS and 53 patients with
LGS following infantile spasms evidenced a relevant per-
ceived efficacy of cannabidiol on seizure frequency (79% of
parents reported fewer seizures while seizures freedomwas
observed in 13% of cases).57 Additional benefits were
observed on sleep, alertness, and mood while the main
reported side effects included somnolence, abnormal appe-
tite, diarrhea, fatigue, and convulsions.56,57
Other Therapeutic Options
Ketogenic Diet
Data on the use of ketogenic diet in patients with LGS
were reported by a limited number of studies with several
methodological limitations (short duration, prominently
retrospective nature, samples including both LGS patients
and other epilepsies).58
A recent retrospective analysis of 71 patients with LGS
who underwent ketogenic diet at Johns Hopkins Hospital
between 1994 and 2012 evidenced a seizure reduction
higher than 50% in 44% of patients after 12months.59 Similar
data (more than 50% of seizure reduction in 47% of patients)
were identified in a meta-analysis in 189 subjects from
18 published studies in the period 1989 to 2010.59 A low
incidence of side effects was reported (including recurring
vomiting, hypoglycemia, constipation, weight loss, kidney
stones, hyperlipidemia, and poor linear growth).57,58 In the
most recent published series ketogenic diet was started after
a median number of six previous antiepileptic drugs while
no experiences in the early stages of treatment have been
reported for LGS.58–60
Surgery
Two main different groups of diagnostic investigations
should be performed before the surgery: tests for the locali-
zation of epileptogenic focus for resection (single-photon
emission computed tomography, positron emission tomog-
raphy, intracranial EEG, and magnetoencephalogram) and
tests for the definition of eloquent cortex tominimize the risk
of neurological deficits related to surgery (electrocorticog-
raphy and fMRI or Wada test if fMRI fails to show a clear
lateralization).61–65 Most of the abovementioned diagnostic
tools are available in a few specialized centers.61 For this
reason, early referral to specialized pediatric neurosurgical
centers is recommended if a clear surgical indication is
defined.61
Two main surgical approaches can be indicated for
children with LGS: (1) resection of the epileptic focus
(lesionectomies, lobar, multilobar, or hemispheric resec-
tions); (2) corpus callosotomy to avoid the interhemispheric
propagation of seizure activity.61
Resective surgery is usually curative, and it should be
preferred if it is possible while corpus callosotomy and vagus
nerve stimulation are palliative approaches.61
The best outcome for resective surgery in LGS was
reported for children younger than 5 years.61 Corpus callos-
otomy often has a higher efficacy in resolving drop attacks
while vagus nerve stimulation offers comparable results for
the other typical seizure types of LGS.61,66
Corpus callosotomy can also precede resective surgery
resulting in a more lateralized epileptic network.61
Vagus Nerve Stimulation
In an old retrospective analysis on a large series of 483 LGS
subjects, without prior surgical treatments, vagus nerve
stimulation resulted in more than 50% of seizure reduction
in 55% of the patients after 18 months.67 In more recent
published studies on different series enrolling between 9 and
50 patients, the efficacy of vagus nerve stimulation was
evaluated over a whole treatment length lasting between 3
and 52 months.61 The percentage of patients in which more
than 50% of seizures reductionwas obtained ranged between
25 and 78%.61 Improvements were also achieved for other
parameters including quality of life, behavior, and cognitive
abilities.61
Differential Diagnosis
The adherence to the abovementioned electroclinical diag-
nostic criteria helps physicians in the differential diagnosis
between LGS and other epileptic syndromes, such as infantile
spasms (discrimination between spasms and tonic seizures),
atypical benign partial epilepsy, partial epilepsies or
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secondarily generalized epilepsies with origin in the frontal
lobe, Doose syndrome (discrimination between myoclonic-
astatic seizures and drop attacks).1,2,17
The differentiation between prolonged spasms and short
tonic seizures can be hard alsowith video-polygraphy even if
spasms usually present in clusters.2,17 In atypical benign
partial epilepsies discriminating diagnostic criteria are the
prolonged periods of seizure freedom, the lack of tonic
seizures and the sleep EEG features (recurring episodes of
continuous spike-waves of slow sleep and generalized par-
oxysmal fast activity).1,2,17 Partial epilepsies or secondarily
generalized epilepsies with origin in the frontal lobe are
characterized by bilateral asymmetrical tonic seizures with
secondary bilateral synchrony at the EEG.2,17 The diagnosis
of Doose syndrome is suggested by the prominence of
myoclonic or myoclonic-astatic seizures and the combina-
tion of fast spike-wave complexes and slow spike-wave
complexes at the EEG.2,17
Outcome
A minority of patients with LGS reaches satisfying levels of
autonomy while up to 76% of them have severe lifelong
limitations because of the intellectual disability and drug-
resistant epilepsy.68,69
Tonic seizures are commonly the most drug-resistant
seizure type while atypical absences and myoclonic seizures
are easier to control with pharmacologic therapy.69 Seizure
freedom achieves 82% in children younger than 5 years with
etiologies treatable with neurosurgery.34,70
The typical diffuse slow spike-waves pattern of LGS is
often replaced with age by focal or multifocal epileptic
discharges while up to 11.8% of recently reported patients
achieved a normalization of the EEG.69
Long-term outcome of a patient with LGS is often disap-
pointingregarding seizurecontrolandcognitivefunctioning in
patientswith earlier onset andhigher frequencyof seizures, in
subjects with constant slower background activity at the EEG
and in cases with a prior West syndrome.1,2,17,29 This state-
ment was not confirmed in a recent study in which no
correlationswere foundbetween seizure onset, etiology, brain
abnormalities on MRI, history of infantile spasms, and intel-
lectual quotient and the importance of appropriate treatments
on seizures and cognitive outcome was stressed.69
Themortality ratehas been reported up to 13.92 per 1,000
person/years in patients with LGS.71 In these subjects death
often results from an accident during seizures or complica-
tions of status epilepticus.4,5
Conclusions
A large body of literature has been published about LGS since
its original characterization, and several pieces of knowledge
on etiology, pathophysiology, clinical presentation, thera-
peutic management, and outcome have been obtained in the
past years. Despite these contributions, LGS remained one of
the most severe age-dependent epileptic encephalopathies,
and a multidisciplinary approach is always mandatory to
support clinical, social, and economic needs of patients and
their families.
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